Welcome to our dedicated page for Sanara MedTech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Sanara MedTech Inc. reported a routine equity compensation event for Chief Operating Officer Jacob A. Waldrop. As 1,551 shares of previously granted restricted stock vested, 378 shares of common stock were withheld by the company to satisfy tax withholding obligations. The filing states that no shares were issued or sold in this transaction. Following the tax withholding disposition, Waldrop directly holds 24,377 shares of Sanara MedTech Inc. common stock.
Sanara MedTech Inc. beneficial ownership disclosure: Baird Trust Company, Baird Financial Corporation and Baird Financial Group, Inc. report aggregated beneficial ownership of 21,075 shares of Common Stock. The filing bases the percentage on 9,167,040 Shares outstanding as of March 20, 2026.
The reporting persons state the shares reflect shared voting and dispositive power held by Baird Trust Company on behalf of clients. Ownership is reported as 5% or less of the class.
Sanara MedTech Inc. reports on its business for the year ended December 31, 2025 as a medical technology company focused on surgical wound care and bone fusion products sold primarily to U.S. hospitals and surgical centers.
The company discontinued its Tissue Health Plus value-based wound care program in mid-September 2025 after persistent losses and unsuccessful efforts to secure outside investment, and now operates as a single surgical-focused segment with THP reported as discontinued operations.
Key products include CellerateRX Surgical hydrolyzed collagen, BIASURGE surgical irrigation, and ALLOCYTE Plus cellular bone matrix, supported by preclinical, clinical and health-economic studies showing improved wound outcomes and modeled cost savings per high-risk spinal patient.
Sanara highlights differentiated surgical technologies, a U.S. commercial footprint exceeding 4,000 hospitals, an expanding patent portfolio, and 40 field sales representatives, while also outlining extensive regulatory, competitive, cybersecurity, operational and indebtedness risks, including revenue and liquidity covenants under a senior secured term loan.
Sanara MedTech Inc. reported strong 2025 growth with net revenue of $103.1 million, up 19% from 2024, and reaffirmed 2026 revenue guidance of $116–$121 million, implying 13%–17% additional growth. Revenue expansion was led by soft tissue repair products, especially CellerateRX Surgical, and supported by a broader distributor and facility network.
Adjusted EBITDA rose to $17.0 million from $9.1 million, and operating cash flow improved to $6.8 million. Gross margin reached 93% in Q4 2025. However, a strategic realignment and the discontinuation of Tissue Health Plus drove a $26.5 million noncash impairment and a full-year net loss of $37.6 million. Management highlights a focused surgical business, higher R&D investment, and long-term growth ambitions in the surgical market.
Mackey Ashley M reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Controller Ashley M. Mackey received a grant of 2,804 shares of common stock as equity compensation. The shares were awarded at no cash cost and increased her direct holdings to 5,067 shares after the transaction.
According to the filing, the 2,804 granted shares are restricted stock issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. They will vest in three equal installments on March 22, 2027, March 22, 2028 and March 22, 2029, provided she remains employed with the company through each vesting date.
Waldrop Jacob A. reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Operating Officer Jacob A. Waldrop received a grant of 13,956 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this equity award, his direct holdings total 24,755 shares of common stock.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22 of 2027, 2028 and 2029, provided he remains employed by Sanara MedTech through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Taylor Elizabeth B reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. granted its Chief Financial Officer, Elizabeth B. Taylor, 12,687 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost and increase her direct holdings to 17,632 common shares following the transaction.
The restricted stock will vest in three equal installments, with one-third vesting on March 22 of 2027, 2028, and 2029, respectively. Vesting is conditioned on her continued employment with Sanara MedTech through each vesting date, aligning a portion of her compensation with the company’s long-term performance.
Yon Seth D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Executive Officer Yon Seth D received a grant of 25,430 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, he directly holds 113,398 common shares.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, provided he remains employed by the company through each vesting date. This represents compensation rather than an open-market share purchase.
Sanara MedTech Inc. reported a routine equity compensation event for its Chief Executive Officer, Yon Seth D. On the vesting of 2,082 shares of previously granted restricted stock, the company withheld 596 shares of common stock to cover tax obligations, using a per-share value of $18.87. The footnote clarifies that no shares were issued or sold on the market in this transaction. Following the tax-withholding disposition, the CEO directly owns 87,968 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Chief Executive Officer Seth D. Yon filed an amended insider report updating a prior tax-related share withholding. The company withheld 414 shares of common stock at $20.44 per share to cover taxes on the vesting of 1,446 restricted shares, correcting an earlier filing that had shown 491 shares withheld. This was a tax-withholding disposition only, and the filing states that no shares were issued or sold in the transaction. After this adjustment, Yon directly holds 88,564 shares of Sanara MedTech common stock.